Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone604-419-3200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.90 million
Profitability
Miscellaneous
Employees79
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Arbutus Biopharma (NASDAQ:ABUS) Frequently Asked Questions
What is Arbutus Biopharma's stock symbol?
Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."
How were Arbutus Biopharma's earnings last quarter?
Arbutus Biopharma Corp (NASDAQ:ABUS) announced its earnings results on Monday, August, 5th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.11. The biopharmaceutical company earned $0.70 million during the quarter, compared to analyst estimates of $0.88 million. Arbutus Biopharma had a negative net margin of 1,948.40% and a negative return on equity of 125.64%. View Arbutus Biopharma's Earnings History.
When is Arbutus Biopharma's next earnings date?
What price target have analysts set for ABUS?
4 brokers have issued 12-month price objectives for Arbutus Biopharma's shares. Their forecasts range from $3.00 to $5.00. On average, they expect Arbutus Biopharma's share price to reach $4.33 in the next year. This suggests a possible upside of 361.0% from the stock's current price. View Analyst Price Targets for Arbutus Biopharma.
What is the consensus analysts' recommendation for Arbutus Biopharma?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Arbutus Biopharma.
Has Arbutus Biopharma been receiving favorable news coverage?
Media stories about ABUS stock have been trending negative this week, according to InfoTrie. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Arbutus Biopharma earned a coverage optimism score of -2.8 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Arbutus Biopharma.
Are investors shorting Arbutus Biopharma?
Arbutus Biopharma saw a drop in short interest in the month of September. As of September 15th, there was short interest totalling 792,800 shares, a drop of 37.6% from the August 15th total of 1,270,000 shares. Based on an average trading volume of 307,500 shares, the short-interest ratio is currently 2.6 days. Approximately 2.2% of the shares of the company are sold short. View Arbutus Biopharma's Current Options Chain.
Who are some of Arbutus Biopharma's key competitors?
Some companies that are related to Arbutus Biopharma include Xenon Pharmaceuticals (XENE), Xeris Pharmaceuticals (XERS), Athersys (ATHX), Kamada (KMDA), LifeVantage (LFVN), Spero Therapeutics (SPRO), Chiasma (CHMA), GlycoMimetics (GLYC), Evelo Biosciences (EVLO), Kalvista Pharmaceuticals (KALV), Mallinckrodt (MNK), NuCana (NCNA), CV Sciences (CVSI), Imprimis Pharmaceuticals (IMMY) and Acasti Pharma (ACST).
What other stocks do shareholders of Arbutus Biopharma own?
Who are Arbutus Biopharma's key executives?
Arbutus Biopharma's management team includes the folowing people:
- Dr. Mark Joseph Murray, Pres, CEO & Director (Age 70)
- Mr. David C. Hastings, CFO & Chief Accounting Officer (Age 58)
- Dr. Gaston Picchio Ph.D., Chief Devel. Officer (Age 56)
- Dr. Michael J. Sofia, Chief Scientific Officer (Age 61)
- Dr. Elizabeth Howard, Exec. VP, Gen. Counsel & Chief Compliance Officer (Age 65)
How do I buy shares of Arbutus Biopharma?
Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Arbutus Biopharma's stock price today?
One share of ABUS stock can currently be purchased for approximately $0.94.
How big of a company is Arbutus Biopharma?
Arbutus Biopharma has a market capitalization of $53.44 million and generates $5.90 million in revenue each year. The biopharmaceutical company earns $-57,060,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Arbutus Biopharma employs 79 workers across the globe.View Additional Information About Arbutus Biopharma.
What is Arbutus Biopharma's official website?
How can I contact Arbutus Biopharma?
Arbutus Biopharma's mailing address is 100-8900 GLENLYON PARKWAY, BURNABY A1, V5J 5J8. The biopharmaceutical company can be reached via phone at 604-419-3200 or via email at [email protected]
MarketBeat Community Rating for Arbutus Biopharma (NASDAQ ABUS)
MarketBeat's community ratings are surveys of what our community members think about Arbutus Biopharma and other stocks. Vote "Outperform" if you believe ABUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
